Cargando…
Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This s...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189124/ https://www.ncbi.nlm.nih.gov/pubmed/33502929 http://dx.doi.org/10.1080/21645515.2020.1871296 |
_version_ | 1783705449732767744 |
---|---|
author | Bianchi, Francesco Paolo Mascipinto, Simona Stefanizzi, Pasquale De Nitto, Sara Germinario, Cinzia Tafuri, Silvio |
author_facet | Bianchi, Francesco Paolo Mascipinto, Simona Stefanizzi, Pasquale De Nitto, Sara Germinario, Cinzia Tafuri, Silvio |
author_sort | Bianchi, Francesco Paolo |
collection | PubMed |
description | The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This study evaluated the proportion of individuals with detectable anti-measles IgG in two groups, those vaccinated with two doses of anti-MMR vaccine and those with a self-reported history of measles infection. Among the 611 students and residents who were tested, 94 (15%) had no detectable protective anti-measles IgG. This proportion was higher among vaccinated individuals (20%; GMT = 92.2) than among those with a self-reported history of measles (6%; GMT = 213.3; p < .0001). After one or two MMR vaccine booster doses, the overall seroconversion rate was 92%. An important proportion of people immunized for measles did not have a protective IgG titer in the years after vaccination, but among those who had a natural infection the rate was three-fold lower. This finding should be considered in the pre-elimination phase, given the resurgence of measles cases among individuals who after being vaccinated lost their circulating IgG after several years, especially if they failed to receive a natural booster. |
format | Online Article Text |
id | pubmed-8189124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-81891242021-06-17 Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study Bianchi, Francesco Paolo Mascipinto, Simona Stefanizzi, Pasquale De Nitto, Sara Germinario, Cinzia Tafuri, Silvio Hum Vaccin Immunother Research Paper The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This study evaluated the proportion of individuals with detectable anti-measles IgG in two groups, those vaccinated with two doses of anti-MMR vaccine and those with a self-reported history of measles infection. Among the 611 students and residents who were tested, 94 (15%) had no detectable protective anti-measles IgG. This proportion was higher among vaccinated individuals (20%; GMT = 92.2) than among those with a self-reported history of measles (6%; GMT = 213.3; p < .0001). After one or two MMR vaccine booster doses, the overall seroconversion rate was 92%. An important proportion of people immunized for measles did not have a protective IgG titer in the years after vaccination, but among those who had a natural infection the rate was three-fold lower. This finding should be considered in the pre-elimination phase, given the resurgence of measles cases among individuals who after being vaccinated lost their circulating IgG after several years, especially if they failed to receive a natural booster. Taylor & Francis 2021-01-27 /pmc/articles/PMC8189124/ /pubmed/33502929 http://dx.doi.org/10.1080/21645515.2020.1871296 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Research Paper Bianchi, Francesco Paolo Mascipinto, Simona Stefanizzi, Pasquale De Nitto, Sara Germinario, Cinzia Tafuri, Silvio Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
title | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
title_full | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
title_fullStr | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
title_full_unstemmed | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
title_short | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
title_sort | long-term immunogenicity after measles vaccine vs. wild infection: an italian retrospective cohort study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189124/ https://www.ncbi.nlm.nih.gov/pubmed/33502929 http://dx.doi.org/10.1080/21645515.2020.1871296 |
work_keys_str_mv | AT bianchifrancescopaolo longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT mascipintosimona longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT stefanizzipasquale longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT denittosara longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT germinariocinzia longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT tafurisilvio longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy |